334 related articles for article (PubMed ID: 33321292)
21. Livestock Gene Editing by One-step Embryo Manipulation.
Navarro-Serna S; Vilarino M; Park I; Gadea J; Ross PJ
J Equine Vet Sci; 2020 Jun; 89():103025. PubMed ID: 32563448
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
23. Genome Editing by CRISPR/Cas9 in Sorghum Through Biolistic Bombardment.
Liu G; Li J; Godwin ID
Methods Mol Biol; 2019; 1931():169-183. PubMed ID: 30652290
[TBL] [Abstract][Full Text] [Related]
24. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
26. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
[TBL] [Abstract][Full Text] [Related]
27. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
29. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
[TBL] [Abstract][Full Text] [Related]
30. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
[TBL] [Abstract][Full Text] [Related]
32. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Verma R; Sahu R; Singh DD; Egbo TE
Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
[TBL] [Abstract][Full Text] [Related]
33. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
Song M
Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
[TBL] [Abstract][Full Text] [Related]
34. Genome editing for human gene therapy.
Meissner TB; Mandal PK; Ferreira LM; Rossi DJ; Cowan CA
Methods Enzymol; 2014; 546():273-95. PubMed ID: 25398345
[TBL] [Abstract][Full Text] [Related]
35. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
[TBL] [Abstract][Full Text] [Related]
36. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
[TBL] [Abstract][Full Text] [Related]
37. Pre-clinical non-viral vectors exploited for
Rouatbi N; McGlynn T; Al-Jamal KT
Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
[TBL] [Abstract][Full Text] [Related]
38. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
39. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.
Mandal PK; Ferreira LM; Collins R; Meissner TB; Boutwell CL; Friesen M; Vrbanac V; Garrison BS; Stortchevoi A; Bryder D; Musunuru K; Brand H; Tager AM; Allen TM; Talkowski ME; Rossi DJ; Cowan CA
Cell Stem Cell; 2014 Nov; 15(5):643-52. PubMed ID: 25517468
[TBL] [Abstract][Full Text] [Related]
40. Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy.
Liu Q; Wang C; Zheng Y; Zhao Y; Wang Y; Hao J; Zhao X; Yi K; Shi L; Kang C; Liu Y
Biomaterials; 2020 Nov; 258():120275. PubMed ID: 32798741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]